Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma

Annals of Allergy, Asthma and Immunology

Volumn 105, Issue 4, 2010, Pages 313-319

  Korn, Stephanie ^a   Schumann, Christian ^b   Kropf, Cornelia ^b   Stoiber, Kathrin ^b   Thielen, Antje ^c   Taube, Christian ^a   Buhl, Roland ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; THEOPHYLLINE;

ADD ON THERAPY; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLERGIC ASTHMA; ARTICLE; BRAIN DISEASE; CHILD; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEART DISEASE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SKIN MANIFESTATION; SYMPTOM; THORAX DISEASE; UNSPECIFIED SIDE EFFECT; WAKEFULNESS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RESPIRATORY FUNCTION TESTS;

EID: 77957913053     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2010.07.007     Document Type: Article

References (39)

1. B. Burrows, R.A. Barbee, M.G. Cline, R.J. Knudson, and M.D. Lebowitz Characteristics of asthma among elderly adults in a sample of the general population Chest 100 1991 935 942
2. U. Ellert, J. Wirz, and T. Ziese Beitrge zur Gesundheitsberichterstattung des Bundes: Telefonischer Gesundheitssurvey des Robert Koch-Instituts (2. Welle) 2006 Robert Koch-Institut Berlin, Germany
3. S.A. Quadrelli, and A.J. Roncoroni Is asthma in the elderly really different? Respiration 65 1998 347 353
4. G.B. Diette, J.A. Krishnan, and F. Dominici Asthma in older patients: factors associated with hospitalization Arch Intern Med 162 2002 1123 1132
5. K. Huss, P.L. Naumann, and P.J. Mason Asthma severity, atopic status, allergen exposure and quality of life in elderly persons Ann Allergy Asthma Immunol 86 2001 524 530
6. R. Buhl, H. Fox, M. Blogg, and C. Reisner Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Eur Respir J 26 suppl 49 2005 48s
7. R.J. Maykut, F. Kianifard, and G.P. Geba Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis J Asthma 45 2008 173 181
8. L. Rogers, C. Cassino, and K.I. Berger Asthma in the elderly: cockroach sensitization and severity of airway obstruction in elderly nonsmokers Chest 122 2002 1580 1586
9. B. Burrows, F.D. Martinez, M. Halonen, R.A. Barbee, and M.G. Cline Association of asthma with serum IgE levels and skin-test reactivity to allergens N Engl J Med 320 1989 271 277
10. E.D. Bateman, H.A. Boushey, and J. Bousquet Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med 170 2004 836 844
11. D.R. Taylor, E.D. Bateman, and L.P. Boulet A new perspective on concepts of asthma severity and control Eur Respir J 32 2008 545 554
12. E.D. Bateman, S.S. Hurd, and P.J. Barnes Global strategy for asthma management and prevention: GINA executive summary Eur Respir J 31 2008 143 178
13. W.C. Moore, and S.P. Peters Severe asthma: an overview J Allergy Clin Immunol 117 2006 487 494
14. P. Chanez, S.E. Wenzel, and G.P. Anderson Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 119 2007 1337 1348
15. M. Humbert, R. Beasley, and J. Ayres Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
16. M. Soler, J. Matz, and R. Townley The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Eur Respir J 18 2001 254 261
17. B.Q. Lanier, J. Corren, W. Lumry, J. Liu, A. Fowler-Taylor, and N. Gupta Omalizumab is effective in the long-term control of severe allergic asthma Ann Allergy Asthma Immunol 91 2003 154 159 (Pubitemid 36999474)
18. R. Buhl, M. Soler, and J. Matz Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Eur Respir J 20 2002 73 78 (Pubitemid 34822924)
19. W. Busse, J. Corren, and B.Q. Lanier Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
20. A.M. Vignola, M. Humbert, and J. Bousquet Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR Allergy 59 2004 709 717
21. S.T. Holgate, A.G. Chuchalin, and J. Hebert Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638
22. J.G. Ayres, B. Higgins, E.R. Chilvers, G. Ayre, M. Blogg, and H. Fox Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma Allergy 59 2004 701 708 (Pubitemid 38850344)
23. J. Bousquet, P. Cabrera, and N. Berkman The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma Allergy 60 2005 302 308
24. R. Buhl, D. Berdel, and C.P. Criee Guidelines for diagnosis and treatment of asthma patients Pneumologie 60 2006 139 177
25. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention www.ginasthma.com Accessed December 2009
26. S. Korn, A. Thielen, S. Seyfried, C. Taube, O. Kornmann, and R. Buhl Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany Respir Med 103 2009 1725 1731
27. C. Kroegel, K. Stoiber, and C. Kropf Practice-related treatment of severe persistent bronchial asthma using omalizumab in Germany: the compliance and utilisation investigation under real-life-study (XCLUSIVE) Eur Respir J 34 2009 315s
28. European Medicines Agency Xolair http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Summary-for-the-public/human/000606/WC500057293.pdf Accessed December 2009
29. D. Price The use of omalizumab in asthma Prim Care Respir J 17 2008 62 72
30. G. Hochhaus, L. Brookman, and H. Fox Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma Curr Med Res Opin 19 2003 491 498
31. M. Law, J.K. Morris, N. Wald, C. Luczynska, and P. Burney Changes in atopy over a quarter of a century, based on cross sectional data at three time periods BMJ 330 2005 1187 1188
32. K. Huss, P.L. Naumann, and P.J. Mason Asthma severity, atopic status, allergen exposure and quality of life in elderly persons Ann Allergy Asthma Immunol 86 2001 524 530
33. L. Rogers, C. Cassino, and K.I. Berger Asthma in the elderly: cockroach sensitization and severity of airway obstruction in elderly nonsmokers Chest 122 2002 1580 1586
34. D.R. Jackola, L.K. Pierson-Mullany, L.R. Daniels, E. Corazalla, A. Rosenberg, and M.N. Blumenthal Robustness into advanced age of atopy-specific mechanisms in atopy-prone families J Gerontol A Biol Sci Med Sci 58 2003 99 107
35. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007 J Allergy Clin Immunol 120 2007 S94 S138
36. J. Bousquet, K. Rabe, and M. Humbert Predicting and evaluating response to omalizumab in patients with severe allergic asthma Respir Med 101 2007 1483 1492 (Pubitemid 46850589)
37. M. Molimard, F. de Blay, A. Didier, and V. Le Gros Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France Respir Med 102 2008 71 76
38. B. Lanier, and G.D. Marshall Jr Unanswered questions on omalizumab (Xolair) patient selection and follow-up Ann Allergy Asthma Immunol 92 2004 198 200
39. J. Corren, T. Casale, and B.Q. Lanier Omalizumab is well tolerated in adolescent/adult patients (>12 years) with moderate-to-severe asthma J Allergy Clin Immunol 115 2005 S75